Education
About Us
Working with TipRanks
Follow Us
Corcept Therapeutics (CORT)
:CORT
Total Valuation
Corcept Therapeutics has a market cap or net worth of $8.17B. The enterprise value is $9.51B.
Market Cap$8.17B
Enterprise Value$9.51B
Share Statistics
Corcept Therapeutics has 105,188,220 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding105,188,220
Owned by Insiders11.43%
Owned by Institutions12.29%
Financial Efficiency
Corcept Therapeutics’s return on equity (ROE) is 0.21 and return on invested capital (ROIC) is 17.09%.
Return on Equity (ROE)0.21
Return on Assets (ROA)0.17
Return on Invested Capital (ROIC)17.09%
Return on Capital Employed (ROCE)0.20
Revenue Per Employee1.35M
Profits Per Employee282.42K
Employee Count500
Asset Turnover0.80
Inventory Turnover0.88
Valuation Ratios
The current PE Ratio of Corcept Therapeutics is 88.8. Corcept Therapeutics’s PEG ratio is 1.15.
PE Ratio88.8
PS Ratio7.71
PB Ratio7.65
Price to Fair Value7.65
Price to FCF26.55
Price to Operating Cash Flow48.00
PEG Ratio1.15
Income Statement
In the last 12 months, Corcept Therapeutics had revenue of 675.04M and earned 139.73M in profits. Earnings per share was 1.35.
Revenue675.04M
Gross Profit664.16M
Operating Income136.95M
Pretax Income161.49M
Net Income139.73M
EBITDA138.29M
Earnings Per Share (EPS)1.35
Cash Flow
In the last 12 months, operating cash flow was 162.85M and capital expenditures -282.00K, giving a free cash flow of 162.57M billion.
Operating Cash Flow162.85M
Free Cash Flow162.57M
Free Cash Flow per Share1.55
Dividends & Yields
Corcept Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.50
52-Week Price Change32.66%
50-Day Moving Average77.99
200-Day Moving Average71.59
Relative Strength Index (RSI)54.53
Average Volume (3m)769.51K
Important Dates
Corcept Therapeutics upcoming earnings date is Feb 18, 2026, TBA (Confirmed).
Last Earnings DateNov 4, 2025
Next Earnings DateFeb 18, 2026
Ex-Dividend Date―
Financial Position
Corcept Therapeutics as a current ratio of 3.35, with Debt / Equity ratio of 1.01%
Current Ratio3.35
Quick Ratio3.26
Debt to Market Cap0.00
Net Debt to EBITDA-0.87
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Corcept Therapeutics has paid 20.28M in taxes.
Income Tax20.28M
Effective Tax Rate0.13
Enterprise Valuation
Corcept Therapeutics EV to EBITDA ratio is 36.74, with an EV/FCF ratio of 25.94.
EV to Sales7.53
EV to EBITDA36.74
EV to Free Cash Flow25.94
EV to Operating Cash Flow25.65
Balance Sheet
Corcept Therapeutics has $421.68M in cash and marketable securities with $6.36M in debt, giving a net cash position of $415.32M billion.
Cash & Marketable Securities$421.68M
Total Debt$6.36M
Net Cash$415.32M
Net Cash Per Share$3.95
Tangible Book Value Per Share$6.58
Margins
Gross margin is 98.19%, with operating margin of 20.29%, and net profit margin of 20.70%.
Gross Margin98.19%
Operating Margin20.29%
Pretax Margin23.92%
Net Profit Margin20.70%
EBITDA Margin20.49%
EBIT Margin20.29%
Analyst Forecast
The average price target for Corcept Therapeutics is $135.33, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$135.33
Price Target Upside74.15% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast17.92%
EPS Growth Forecast-26.13%